Abstract
Introduction: Axillary ultrasound (AUS) for axillary staging of breast cancer is a standard procedure now to identify metastatic lymph nodes (LN). In 2009 we retrospectively audited AUS for axillary staging and found a sensitivity of 57.7% and specificity of 92.7% in our breast unit. However, only 50% of abnormal nodes were AUS-guided biopsied. In this study we aim to close the audit cycle by assessing whether the prevalence of AUS has increased and more abnormal nodes have been biopsied.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have